B. Hendrickson

发表

Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions

Susan P Duke, Susan P. Duke, Jonathan H Seltzer, 2019, Therapeutic Innovation & Regulatory Science.

Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting

R. Kilpatrick, J. Curtis, B. Hendrickson, 2019, RMD Open.

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

Stanley B. Cohen, C. Zerbini, K. Winthrop, 2019, Annals of the Rheumatic Diseases.

Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study

K. Winthrop, B. Hendrickson, A. Kivitz, 2022, RMD Open.

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis

C. Leonardi, C. Ryan, B. Hendrickson, 2018, American Journal of Clinical Dermatology.

A Framework for Safety Evaluation Throughout the Product Development Life-Cycle

Eric Lewis, Greg Ball, Frank W Rockhold, 2019, Therapeutic Innovation & Regulatory Science.

Safety, tolerability, and pharmacodynamics of an anti-interleukin-1α/β dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study.

M. Karsdal, S. Abramson, M. Attur, 2017, Osteoarthritis and cartilage.

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

J. Silverberg, T. Bieber, K. Reich, 2021, The Lancet.

THU0167 SAFETY PROFILE OF UPADACITINIB IN RHEUMATOID ARTHRITIS: INTEGRATED ANALYSIS FROM THE SELECT PHASE 3 CLINICAL PROGRAM

C. Zerbini, G. Burmester, Yoshiya Tanaka, 2019, Poster Presentations.

Monitoring Drug Safety in Rheumatoid Arthritis Prevention Trials.

B. Hendrickson, M. Weinreich, T. Doan, 2019, Clinical therapeutics.

RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study

A. Cherniack, B. Hendrickson, C. Cuff, 2017, Advances in Therapy.

Aggregate Safety Assessment Planning for the Drug Development Life-Cycle

Greg Ball, Barbara A Hendrickson, William Wang, 2021, Therapeutic Innovation & Regulatory Science.

FRI0141 CHARACTERIZATION OF SERIOUS INFECTIONS WITH UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS

I. McInnes, C. Selmi, K. Winthrop, 2020 .

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies.

J. Silverberg, A. Paller, J. Thyssen, 2022, The Journal of allergy and clinical immunology.

Value and Implementation of the Aggregate Safety Assessment Plan

B. Hendrickson, Lothar Tremmel, D. Bennett, 2023, Pharmaceutical Medicine.

FRI0164 Safety, Tolerability, And Functional Activity of ABT-122, A Dual TNF- and IL-17A–Targeted DVD-IG™, Following Single-Dose Administration in Healthy Subjects

M. Ruzek, B. Hendrickson, A. Ivanov, 2015 .

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

C. Zerbini, K. Winthrop, B. Hendrickson, 2020, Annals of the Rheumatic Diseases.

Using the Bayesian detection of potential risk using inference on blinded safety data (BDRIBS) method to support the decision to refer an event for unblinded evaluation

S. Mukhopadhyay, A. Hartford, B. Hendrickson, 2021, Pharmaceutical statistics.